Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings.
BACKGROUND
Accumulating evidence implicates a fundamental link between the immune system and atherosclerosis. Toll-like receptors are principal sensors of the innate immune system. Here we report an assessment of the role of the TLR2 pathway in atherosclerosis associated with a high-fat diet and/or bacteria in ApoE(+/-) mice.


RESULTS
To explore the role of TLR2 in inflammation- and infection-associated atherosclerosis, 10 week-old ApoE(+/-)-TLR2(+/+), ApoE(+/-)-TLR2(+/-) and ApoE(+/-)-TLR2(-/-) mice were fed either a high fat diet or a regular chow diet. All mice were inoculated intravenously, once per week for 24 consecutive weeks, with 50 microl live Porphyromonas gingivalis (P.g) (10(7) CFU) or vehicle (normal saline). Animals were euthanized 24 weeks after the first inoculation. ApoE(+/-)-TLR2(+/+) mice showed a significant increase in atheromatous lesions in proximal aorta and aortic tree compared to ApoE(+/-)-TLR2(+/-) and ApoE(+/-)-TLR2(-/-) mice for all diet conditions. They also displayed profound changes in plaque composition, as evidenced by increased macrophage infiltration and apoptosis, increased lipid content, and decreased smooth muscle cell mass, all reflecting an unstable plaque phenotype. SAA levels from ApoE(+/-)-TLR2(+/+) mice were significantly higher than from ApoE(+/-)-TLR2(+/-) and ApoE(+/-)-TLR2(-/-) mice. Serum cytokine analysis revealed increased levels of pro-inflammatory cytokines in ApoE(+/-)-TLR2(+/+) mice compared to ApoE(+/-)-TLR2(+/-) and TLR2(-/-) mice, irrespective of diet or bacterial challenge. ApoE(+/-)-TLR2(+/+) mice injected weekly for 24 weeks with FSL-1 (a TLR2 agonist) also demonstrated significant increases in atherosclerotic lesions, SAA and serum cytokine levels compared to ApoE(+/-)-TLR2(-/-) mice under same treatment condition. Finally, mass-spectrometry (MALDI-TOF-MS) of aortic samples analyzed by 2-dimensional gel electrophoresis differential display, identified 6 proteins upregulated greater than 2-fold in ApoE(+/-)-TLR2(+/+) mice fed the high fat diet and inoculated with P.g compared to any other group.


CONCLUSIONS
Genetic deficiency of TLR2 reduces diet- and/or pathogen-associated atherosclerosis in ApoE(+/-) mice, along with differences in plaque composition suggesting greater structural stability while TLR-2 ligand-specific activation triggers atherosclerosis. The present data offers new insights into the pathophysiological pathways involved in atherosclerosis and paves the way for new pharmacological interventions aimed at reducing atherosclerosis.
Madan
Monika
M
Department of Periodontology and Oral Biology, School of Dental Medicine, Boston University, Boston, Massachusetts, United States of America.
Amar
Salomon
S
D000818:Animals; D001011:Aorta / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics; D050197:Atherosclerosis / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D004032:Diet; D005947:Glucose / Q000378:metabolism; D007107:Immune System; D007113:Immunity, Innate; D007249:Inflammation; D051379:Mice; D008957:Models, Genetic; D040901:Proteomics / Q000379:methods; D000685:Serum Amyloid A Protein / Q000096:biosynthesis; D051195:Toll-Like Receptor 2 / Q000378:metabolism*
D001057:Apolipoproteins E; D000685:Serum Amyloid A Protein; D051195:Toll-Like Receptor 2; D002784:Cholesterol; D005947:Glucose
Am Heart J. 1999 Nov;138(5 Pt 2):S534-6
10539867
Innate Immun. 2008 Feb;14(1):39-49
18387918
J Biol Chem. 2000 Apr 14;275(15):11058-63
10753909
Nat Rev Immunol. 2001 Nov;1(2):135-45
11905821
Circulation. 2004 Jun 8;109(22):2801-6
15123526
Atherosclerosis. 2001 Feb 1;154(2):377-85
11166770
N Engl J Med. 1999 Jan 14;340(2):115-26
9887164
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75
10807742
J Leukoc Biol. 1998 Jun;63(6):650-7
9620655
Nat Med. 2004 Apr;10(4):416-21
15034566
Infect Immun. 2002 Dec;70(12):6658-64
12438339
Atherosclerosis. 2007 Jan;190(1):62-72
16563401
Cardiovasc Res. 2005 Apr 1;66(1):162-9
15769459
Circulation. 2001 Dec 18;104(25):3103-8
11748108
Methods Enzymol. 1996;269:37-41
8791635
Circ Res. 2002 Aug 23;91(4):281-91
12193460
Atherosclerosis. 1999 Dec;147(2):213-25
10559506
Ann Periodontol. 2002 Dec;7(1):72-8
16013219
Circulation. 2000 Dec 19;102(25):3046-52
11120693
Cardiovasc Res. 2000 Feb;45(3):736-46
10728396
Circ Res. 2001 Sep 28;89(7):E41-5
11577031
Int Immunol. 2001 Jul;13(7):933-40
11431423
Circ Res. 1994 Jul;75(1):1-7
8013067
Am Heart J. 1999 Nov;138(5 Pt 2):S419-20
10539839
Atherosclerosis. 2008 Apr;197(2):504-14
17412346
Annu Rev Immunol. 2002;20:197-216
11861602
Infect Immun. 2004 Mar;72(3):1657-65
14977973
J Dermatol Sci. 2004 Apr;34(2):73-82
15033189
J Endotoxin Res. 2000;6(5):393-6
11521061
Cell. 2002 Dec 27;111(7):927-30
12507420
J Exp Med. 1998 Jun 15;187(12):2097-101
9625770
Nature. 2002 Dec 19-26;420(6917):868-74
12490960
J Immunol. 2002 Jul 1;169(1):10-4
12077222
J Clin Invest. 2005 Nov;115(11):3149-56
16211093
Ann N Y Acad Sci. 2001 Dec;947:419-23
11795305
Circulation. 2002 Mar 5;105(9):1135-43
11877368
Circulation. 2000 Apr 18;101(15):1758-9
10769272
EMBO J. 2000 Jul 3;19(13):3325-36
10880445
Atherosclerosis. 2002 Jan;160(1):91-102
11755926
Circulation. 2002 Mar 12;105(10):1158-61
11889007
J Biol Chem. 1999 Nov 19;274(47):33179-82
10559185
Circulation. 2002 Feb 19;105(7):861-7
11854128
Clin Chem. 2001 Mar;47(3):403-11
11238289
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10679-84
15249654
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):727-33
12006383
Microbiol Immunol. 2002;46(3):151-8
12008923
Circulation. 2004 Sep 21;110(12):1678-85
15353494